Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$2.1K-85.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andrew Simpson
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 14
- Beta
- 1.77
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -42.11
Financials
Revenue
$2.1K-86.0%Net Income
$-3.17MEBITDA
$-2.90MFree Cash Flow
$-1.32BEPS (diluted)
$-0.86Shares Outstanding (diluted)
3.67M+10971.7%Operating Expenses
$2.94BCash & Debt
$29.91MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $4.3K | $-9.14M | $-3.48 |
| 2025 | $4.3K | $-8.77M | $-9.34 |
| 2024 | $18.6K | $-6.61M | $-18.74 |
| 2023 | $5.2K | $-6.35M | $-79.92 |
| 2022 | $14.4K | $-4.83M | $-145.48 |
| 2021 | $25.6K | $-2.45M | $-77.89 |
| 2020 | $64.2K | $-3.81M | $-115.69 |
Valuation
HSCShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-25.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Negative
HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device Southlake, TX, Oct. 06, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted 510(k) clearance (K260005) for its MyoVista® wav…
View source ↗ - Newsbusinesswire.com·6d ago·Neutral
…ttman joins Fortitude's executive leadership team as the Company prepares for its previously announced proposed business combination with HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences”). In her role, Pittman will work along.
View source ↗ - Newszacks.com·21d ago·Negative
HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates HeartSciences Inc. (HSCS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $1.58 per share a year ago.
View source ↗
Earnings
Mon, Dec 21(in 3 months)
Consensus estimate $-0.62 per share
Typical surprise +5.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Sep 14$-0.86 vs $-0.72miss
- Thu, Jul 23$-0.88 vs $-0.66miss
- Mon, Mar 16$-0.63 vs $-0.84beat
- Mon, Dec 15$-0.85 vs $-0.90beat
- Thu, Sep 11$-1.58 vs $-2.41beat
- Thu, Jul 24$-1.88 vs $-2.51beat
Estimates and results for HSCS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HSCS officers and directors.
- Bought
- —
- Sold
- $16k
0 trades
1 trade
- Hilz Mark Tsold
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HSCS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.